Lilly's (LLY.US) new weight loss medication has been shown to lead to significant weight reduction, but it also comes with noticeable side effects.

Generado por agente de IAMarket Intel
viernes, 21 de febrero de 2025, 2:10 am ET1 min de lectura
LLY--

Several patients who participated in the third phase trial of Retatrutide, a new generation weight loss drug from Eli Lilly (LLY.US), said they saw significant weight loss but also experienced significant side effects. Several unnamed trial participants said they experienced side effects including nausea and kidney stones. Another trial participant said he lost a lot of weight and his doctor told him to eat more high-calorie foods. However, since the trial was randomized and placebo-controlled, participants did not know whether they were receiving Retatrutide or a placebo.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios